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 Introduction 
Oxcarbazepine is indicated as monotherapy or adjunctive therapy in the treatment of partial 
and generalized tonic-clonic seizures in adults and children (Verrotti et al., 2010; Wellington 
and Goa, 2001). Oxcarbazepine undergoes rapid pre-systemic reduction metabolism resulting in 
the formation of its active monohydroxy metabolite 10-hydroxycarbazepine (MHD). MHD has a 
chiral centre yielding two enantiomers (S-(+)- and R-(-)-MHD), which show similar effects in 
vitro and in animal models for anticonvulsant activity (May et al., 2003; Schmutz et al., 1994; 
Volosoc et al., 2000, 1999). The absolute bioavailability of oxcarbazepine assessed from MHD 
plasma data is 99% (Flesch et al., 2011) and its apparent volume of distribution (V/F) is 7.8 to 
12.5 L/kg in epileptic patients (Dickinson et al., 1989). Protein binding is approximately 59% for 
oxcarbazepine (Patsalos et al., 1990), whereas even lower values were found for  R-(-)-MHD and 
S-(+)-MHD (20 and 23%, respectively) (Fortuna et al., 2010). Most of the administered dose of 
oxcarbazepine (79%) is eventually excreted through the kidneys as glucuronide conjugate MHD 
and as unchanged MHD (Flesch et al., 2011). Less than 1% is excreted as unchanged 
oxcarbazepine and 9% as inactive glucuronide conjugates of oxcarbazepine  (Tecoma, 1999; 
Wellington and Goa, 2001). In addition, about 4% of MHD is oxidized with formation of the 
inactive metabolite 10,11-dihydro-10,11-trans-dihydroxycarbazepine (DHD) (Flesch et al., 2011; 
Paglia et al., 2007; Schütz et al., 1986; Volosoc et al., 2000).  
The extensive metabolic conversion to MHD is supported by data in healthy subjects who were 
administered a single 250-mg MHD infusion over 30 min. In these subjects, volume of 
distribution estimates were found to be 9.0 and 8.4 L for R-(-)-MHD and S-(+)-MHD, respectively 
(Flesch et al., 2011).In addition, enantioselective elimination was observed, as indicated by 
mean clearance (CL) values of 4.3 L/h for R-(-)-MHD and 3.1 L/h for S-(+)-MHD. These 
differences result in plasma accumulation of the S-(+)-MHD enantiomer relatively to the other 
enantiomer, with area under the plasma concentration vs. time curve (AUC) of 119.5 vs. 166.8 
mol.h/L. Similar findings were observed after oral administration of oxcarbazepine  to healthy 
subjects,  with AUC values of 63.9 mol.h/L for R-(-)-MHD and  241.0 for S-(+)-MHD mol.h/L 
(Flesch et al., 2011). 
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Previous studies have shown that oxcarbazepine and MHD are substrates of the P-glycoprotein 
(P-gp) efflux transporter (Clinckers et al., 2008, 2005; Zhang et al., 2011). P-gp can have major 
influence on the processes of absorption, distribution and elimination of drugs (Marzolini et al., 
2004). P-gp may also affect the absorption rate and bioavailability of drugs administered orally 
(Estudante et al., 2013; Fortuna et al., 2012; Shugarts and Benet, 2009). On the other hand, the 
expression of P-gp in the blood brain-barrier limits the penetration of (substrate) moieties into 
the central nervous system (CNS), thereby potentially reducing their pharmacological effects 
(Yamamoto et al., 2016). Changes in the expression of P-gp in the brain are associated with 
differences in antiepileptic drug levels in the brain parenchyma. It has also been shown that 
seizures in mice increase the MDR1 expression in the hippocampus and reduce the 
brain/plasma concentration ratios of phenytoin (Marchi et al., 2005; Rizzi et al., 2002). 
Considering the possible involvement of the P-gp over-expression on the mechanisms 
underlying pharmacoresistance to epilepsy treatment, the inhibition of P-gp function by 
selective blockers may become a viable strategy to facilitate the distribution of drugs into the 
CNS. However, from a clinical safety perspective, implementation of such a strategy requires 
further understanding of the impact of P-gp inhibition on systemic exposure. Verapamil is a 
known P-gp inhibitor in various tissues including the brain (Clinckers et al., 2008),  gut (Lemma 
et al., 2006) and liver (Lemma et al., 2006). Moreover, verapamil was found to potentiate the 
anticonvulsant activity of oxcarbazepine in an experimental seizure model in rats. This effect 
was associated with increased MHD levels in the rat brain (Clinckers et al., 2008, 2005). The 
current study aimed to characterize the pharmacokinetics of oxcarbazepine and the MHD 
enantiomers in the presence and absence of verapamil in humans using a model-based 
population pharmacokinetic approach. This investigation will allow the assessment of the 
impact of P-gp inhibition on systemic drug exposure and provide the basis for further 
investigation of the use of oxcarbazepine in combination with P-gp inhibitors in patients.  
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1. Materials and methods 
2.1 Clinical trial protocol 
Details of the clinical trial used in this analysis have been described previously (de Jesus 
Antunes et al., 2016). Briefly, 12 (8 female and 4 male) healthy subjects were enrolled into an 
open label, randomized, two-way crossover pharmacokinetic study. The study protocol was 
approved by the local research ethics committee.  Individual subjects were enrolled into the 
study after signing an informed consent form. Only non-obese, non-smokers healthy adult 
subjects with clinical laboratory results within normal limits were included. Patient 
characteristics are shown in Table 1. 
Subjects received repeated doses of either oxcarbazepine alone (defined as occasion O) or 
oxcarbazepine and verapamil (defined as occasion O+V). There was a washout period of 30 days 
between treatments. On occasion O, oxcarbazepine was administered as oral dose of 300 mg 
every 12 hours for 5 days. On the fifth day, a 9th dose of the drug was administered and steady 
state blood samples were collected at 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 
8, 10 and 12 h post oxcarbazepine dose. On occasion O+V, the subjects received oral dose of 
300 mg of oxcarbazepine every 12 hours and oral dose of 80 mg of verapamil every 8 hours, at 
the same time. On the fifth day, after fasting for at least 10 h, the 13th dose of verapamil was 
administered and after 1 h the 9th dose of OXC. Serial blood samples were collected as 
described above for the O occasion. A detailed description of the analysis of oxcarbazepine and 
MHD enantiomers can be found in a previous publication by our group (Antunes et al., 2013), 
and is summarized as supplemental material. 
 
2.2 Pharmacokinetic modelling 
Nonlinear mixed effects modelling was performed in NONMEM (version 7.2) using the first-
order conditional estimation method with the interaction option. Model building criteria 
included a decrease in the objective function value (OFV), a successful minimisation, adequate 
standard error of estimates and number of significant digits, and evaluation of parameter 
correlation. 
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2.2.1 Pharmacokinetic model development for oxcarbazepine 
Two and three-compartment disposition models with first order elimination were considered to 
describe the pharmacokinetics of oxcarbazepine. We evaluated both a first order absorption 
process and a transit compartment model (Eq. 1) (Savic et al., 2007). 
𝐾𝑡𝑟 =
𝑛+1
𝑀𝑇𝑇
          (1) 
where Ktr is a transfer rate constant from nth-1 compartment to the nth compartment with n 
being the number of transit compartments, and MTT is the mean transit time (Savic et al., 
2007).  
 
2.2.2. Integrated model for oxcarbazepine and MHD enantiomers 
The parameter estimates obtained for oxcarbazepine were fixed for the subsequent steps 
during which an integrated model was developed to account for the disposition of the 
metabolite enantiomers (Zhang et al., 2003). One and two compartment models were 
evaluated for describing the concentration-time profiles of the MHD enantiomers. 
The absolute formation rates of MHD were not available from the same subjects due to a lack 
of urine data. Therefore, we fixed the fraction of oxcarbazepine metabolized to MHD (FMET) to a 
previously published value of 0.79 (Schütz et al., 1986), in order to estimate the total clearance 
to the MHD enantiomers (CLm). We then used the relative fraction of the MHD formation 
clearances for R-(-)-MHD (CLmR) and S-(+)-MHD (CLmS) on the AUC fractions of each 
enantiomer relative to the total metabolite AUC calculated by non-compartmental analysis (Eq. 
2-5).  
 CLm=𝐹𝑀𝐸𝑇 ∗ 𝐶𝐿𝑡𝑜𝑡𝑎𝑙         (2) 
FRS =
(AUCR−(−)−MHD)
(AUCR−(−)−MHD)+(AUCS−(+)−MHD)
       (3)                                                                                
CLmR = CLm ∗ FRS          (4) 
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CLmS = CLm ∗ (1 − FRS)         (5)                                                                                                                 
Model building procedures and criteria, including the evaluation of covariate factors, inter-
individual variability (IIV) and residual variability models were implemented as described 
previously for oxcarbazepine.   
 
2.2.3. Covariate model development 
Verapamil co-administration was treated as a discrete covariate, and was tested the 
parameters for absorption, bioavailability (F), CL/F and V/F. It was hypothesised that increased 
uptake of oxcarbazepine and MHD could occur after administration of verapamil due to the 
decrease in transport of drugs  back into the intestinal lumen (Clinckers et al., 2008, 2005; 
Lemma et al., 2006). 
Because of the small sample size of this dataset (N=12) and a considerably homogeneous 
population in terms of their baseline demographic characteristics, additional data-driven 
covariate modelling as potential predictors for IIV was not considered feasible. Instead, a priori 
allometric scaling of CL/F and V/F was implemented for both oxcarbazepine and MHD 
enantiomers using the following relationship: 
θ𝑖 = θ𝑝 ∗ (
𝐵𝑊𝑖
68
)𝑚         (6) 
in which θi is the parameter value of the ith subject with body weight BWi,  θp the typical value 
of the parameter in the population with a body weight of 68 Kg, BWi is the body weight of the 
ith subject, m is the exponent value fixed to 0.75 for CL/F and 1 for V/F (Anderson and Holford, 
2008). 
 
2.2.4. Statistical model development 
The IIV of the PK parameters was estimated using an exponential model expressed as: 
θ𝑖 = θ𝑝 ∗ 𝑒
η𝑖           (7) 
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where θi represents the parameter value of the ith subject, θp the typical value of the parameter 
in the population, and ηi normally distributed with mean 0 and variance ω2. 
Inter-occasion variability (IOV) was tested on absorption parameters, distribution volumes, and 
clearance (CL/F) and was included as follows: 
θ𝑖 = θ𝑝 ∗ 𝑒
η𝑖+κo         (8) 
where κo represents occasion o normally distributed with mean 0 and variance π2. 
We evaluated proportional, additive and combined residual error models, for each enantiomer 
of OXC and MHD separately: 
C𝑖𝑗,𝑜𝑏𝑠 = C𝑖𝑗,𝑝𝑟𝑒𝑑 ∗ (1 + ε𝑖𝑗,𝑝𝑟𝑜𝑝) + ε𝑖𝑗,𝑎𝑑𝑑       (9) 
where Cij,obs and Cij,pred are the observed and predicted concentration for the ith individual and 
the jth observation, εij,add and  εij,prop are normally distributed with mean 0 and variance σ2, and 
where εij,add = 0 for a proportional error model, and εij,prop=0 for an additive error model. 
 
2.2.5. Model evaluation 
Model evaluation was based on graphical and statistical methods, including goodness of fit, 
correlation matrix for fixed vs. random effects, correlation matrix between parameters and 
covariates, mirror plots, visual predictive check (VPC), normalised prediction distribution errors 
(NPDE) and the posterior predictive check (PPC)(Nguyen et al., 2016).  Comparison of 
hierarchical models was based on the likelihood ratio test, with a decrease in objective function 
value (OFV) of 3.84 corresponding to a p-value of <0.05 at 1 degree of freedom. 
 
3. Results 
A total of 185 plasma samples were included into the analysis, with a mean number of 16 
samples per subject. Non-compartmental analysis (NCA, Table 2) indicated rapid absorption of 
oxcarbazepine (tmax 0.9-1.2 h) and conversion into MHD enantiomers (tmax 2.8-3.5 h) (de Jesus 
Antunes et al., 2016). Oxcarbazepine was rapidly absorbed and its majority directly converted 
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to the MHD enantiomers (Figure 1). MHD elimination was slow (t1/2 11.7-13.5 h). The 
administration of verapamil increased exposure with approximately 10 %, based on the AUC0-12.  
A two-compartment disposition model (Figure 2) with three absorption transit compartments 
and first order elimination best described the plasma concentration profiles of oxcarbazepine 
(Table 3). In addition, IIV was identified for MTT, F, central V/F, and CL/F. Whereas fixed effect 
parameters were estimated with good precision (RSE <21.9%), IIV estimates showed high RSE 
values. This is probably related to the low number of patients included in this study. Given the 
differences in the absorption profiles observed between the treatment periods, IOV was used 
to describe the variability in MTT. Overall, co-administration of verapamil caused a small 
increase (12%) in the relative apparent bioavailability of oxcarbazepine. It was not identified as 
a significant factor on other parameters (e.g., CL, V, absorption rate constant) during the 
covariate analysis.   
Metabolite formation and elimination kinetics was characterised by two additional one 
compartment models both R-(-)-MHD and S-(+)-MHD, respectively. Separate clearances for the 
enantiomers were not uniquely identifiable. As only a study in which the metabolite 
enantiomers are administered separately would allow estimation of independent enantiomer 
CL/F estimates, the model was parameterised using single CL/F parameter for both moieties. 
On the other hand, we were able to estimate separate V/F values for both enantiomers, 
including a shared random effect parameter describing IIV, i.e. assuming the same distribution 
characteristics of each enantiomer. The estimation of FRS based on the AUC0-12h was the best 
possible estimate that we could obtain given the available data.   
For both oxcarbazepine and its metabolite, a proportional error model was used to describe the 
residual variability. The detailed model building steps are presented in Table S1. No effect of 
verapamil co-administration on metabolite PK parameters (clearance, volume) was identified. 
Model diagnostics indicated adequate goodness-of-fit for the final model (Figure 3). In addition, 
the simulation-based NPDE analysis revealed acceptable differences in model predictions and 
observations (Figure S1). The plots in Figure 4 describe the visual predictive check obtained for 
the final model. The plots show good model performance relative to the observed data, even 
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though a slight over-prediction occurs for both MHD enantiomers. Mirror plots revealed that 
the variance-covariance structure was well characterised, as the simulated datasets reproduced 
the dispersion pattern observed in the original data (Figure S2). The final step in the evaluation 
of the performance of the final model included posterior predictive checks (PPC) based on a 
secondary pharmacokinetic parameter (i.e., AUC0-12). As shown in Figure 5, the model 
adequately predicted AUC0-12 for both the parent drug and its MHD enantiomers. 
 
4. Discussion 
Effective treatment and management of epileptic seizures remains a challenging objective in 
clinical practice (Piana et al, 2014). Whilst variation in response to treatment is often assigned 
to the heterogeneity in the underlying disease progression and other clinical and genetic 
factors, interindividual differences in drug exposure also result in treatment failure. Population 
modelling approaches offer an opportunity to assess drug disposition properties taking into 
account pharmacokinetic variability. We have developed an integrated population model to 
describe the pharmacokinetics of oxcarbazepine and its MHD enantiomers in healthy subjects 
after oral administration of oxcarbazepine alone and in combination with verapamil. The 
pharmacokinetic model adequately characterized the absorption and disposition of 
oxcarbazepine and the formation of its active metabolite enantiomers, including the 
identification of the associated IIV. To our knowledge, it is the first time a population 
pharmacokinetic model is developed for both moieties. 
In agreement with a previous study (Dickinson et al., 1989), the absorption of oxcarbazepine 
did not follow first-order kinetics. Instead, a transit compartment was required to allow 
accurate description of the upswing phase of the concentration profile in plasma. The approach  
is an attractive alternative for characterizing delayed absorption profiles, especially when IIV in 
the rate and extent of absorption is high (Savic et al., 2007).  
Even though the pharmacokinetics of MHD as racemic mixture has been previously described in 
adult epileptic patients (Park et al., 2012; Yu et al., 2016), no data are available that provides 
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insight into the formation rate of the MHD enantiomers after oral administration. Here we 
showed that the disposition characteristics of both MHD enantiomers can be accurately 
described by a one-compartment model. Given the relevance of active metabolite for the 
overall clinical response to oxcarbazepine, it is important to show whether formation clearance 
represents a rate limiting step in the disposition of the MHD enantiomers. Flesch and 
collaborators have studied the pharmacokinetics of MHD after intravenous administration and 
reported total clearance values of 4.3 L/h for R-(-)-MHD and 3.1 L/h for S-(+)-MHD, whereas our 
estimates for CL/F were 2.01 L/h for both enantiomers (Flesch et al., 2011). These differences 
clearly suggest that formation rate does reduce the total clearance of MHD in vivo. Distribution 
properties of parent drug and metabolites were also found to differ after intravenous and oral 
administration.  A rather large V/F at steady-state was obtained after oral administration of 
oxcarbazepine (587 L). These findings are in agreement with the results reported by (Dickinson 
et al., 1989) in patients with epilepsy (523-839 L). The estimates of V/F for the active 
metabolites showed somewhat limited distribution of the enantiomers, with estimates of 23.6 L 
and 31.7 L for R-(-)- and S-(+)-MHD respectively. Previously, higher values have been reported 
for volume of distribution, with estimates of 54.7 L and 45.9 L for R-(-)- and S-(+)-MHD,  
respectively  (Flesch et al., 2011).  
Despite its inhibitory P-gp activity, our analysis reveals that verapamil has limited impact on the 
systemic pharmacokinetics of oxcarbazepine. Co-administration of verapamil resulted in an 
increase of the oxcarbazepine relative bioavailability of only 12 % (Table 3). This small 
difference reflects previous findings in pre-clinical species, where co-administration of 
verapamil and oxcarbazepine resulted in limited changes to systemic pharmacokinetics despite 
a major increase in the concentrations of MHD in the brain (Clinckers et al., 2008). 
Unfortunately, verapamil pharmacokinetic data was not collected in our study and 
consequently, no information is available regarding the time course of P-gp inhibition. Yet, at 
steady state it can be anticipated that inhibitory effects are relatively constant, justifying the 
rationale for treating verapamil co-administration as a discrete covariate factor.  
We acknowledge some limitations in our analysis, which are worth mentioning. First, apparent 
parameter estimates have been obtained due to the lack of urine data for each of the moieties. 
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Second, full characterisation of enantioselective metabolism would also benefit from a larger 
population size, but recruitment of a larger group of subjects was not feasible.  Instead, we 
have resorted to published data whenever possible. Given the longer half life of MHD, of note is 
also the use of individual ratios of AUC0-12 for the calculation of FRS. An attempt to derive FRS 
based on mean AUC estimates over an interval of 48 h (AUC0-48h) (Flesch et al., 2011) resulted in 
unsuccessful minimisation. Lastly, additional factors, such as co-medications would have to be 
included in a covariate analysis if patients were to be considered (Park et al., 2012). 
 
5. Conclusion 
An integrated population model has been identified that describes the pharmacokinetics of 
oxcarbazepine, including the formation and disposition of its active metabolite enantiomers. 
Concurrent estimation of clearances suggested that MHD formation may be rate limiting. As 
such, this process represents a critical step for the onset of the antiepileptic effects of MHD. 
Verapamil co-administration was associated with a modest 12% increase of the oxcarbazepine 
relative bioavailability, but not on any other parameter describing the disposition of 
oxcarbazepine of MHD enantiomers. The overall clinical relevance of this effect is likely to be 
negligible. However, assuming that inhibition of P-gp transport along the blood-brain barrier is 
comparable to preclinical findings (Clinckers et al., 2008), integration of this pharmacokinetic 
with functional measures of cerebral perfusion could shed light on the pharmacodynamic 
effects of oxcarbazepine and MHD in the brain and the potential role of P-gp inhibitors as 
therapeutic adjuvant.   
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Table legends 
 
Table 1 Demographic and biochemical data of the healthy subjects (n=12).  
 
Table 2 Non-compartmental estimates of oxcarbazepine (OXC) and the 10-hydroxycarbazepine (MHD) 
enantiomers in plasma of healthy volunteers (n=12) after oxcarbazepine alone treatment (Occasion O) 
or OXC + verapamil treatment (Occasion O+V).   
 
Table 3 Population pharmacokinetic parameter estimates for oxcarbazepine (OXC) and the 10-
hydroxycarbazepine (MHD) enantiomers. 
 
Figure Legends 
Figure 1 Pharmacokinetics of oxcarbazepine (OXC), R-(-)-MHD and S-(+)-MHD in plasma. The 
data are expressed as mean ± standard deviation, with and without verapamil (VER) co-
administration.  
 
Figure 2 A schematic overview of the population pharmacokinetic model for oxcarbazepine 
(OXC) and 10-hydroxycarbazepine (MHD) enantiomers. V, volume of distribution; Vc, central 
distribution volume; Vp, peripheral distribution volume; VRMHD, central distribution volume R-(-)-
MHD; VSMHD, central distribution volume S-(+)-MHD; CLmR, formation clearance for R-(-)-MHD; 
CLmS, formation clearance for S-(+)-MHD; CLother, formation clearance for other metabolites or 
elimination of unchanged OXC; F1, relative bioavailability; Ktr, transfer rate constant; Q, inter-
compartmental clearance. 
 
Figure 3 Goodness-of-fit of final population pharmacokinetic model of oxcarbazepine (OXC), R-
(-)-MHD and S-(+)-MHD – Observed (DV) versus population predicted and individual predicted 
concentrations (PRED, IPRED), conditional weighted residuals (CWRES) versus PRED. ○, 
Occasion O (OXC alone treatment); ●, Occasion O+V (OXC+verapamil treatment). 
17 
 
 
Figure 4 Visual predictive check (VPC) for final PK model for oxcarbazepine (OXC), R-(-)-MHD 
and S-(+)-MHD. The dashed lines represent the 5th, and 95th percentiles of simulated data 
(n=1000). The solid lines represent the 50th of simulated data (n=1000). Occasion O (OXC alone 
treatment); Occasion O+V (OXC+verapamil treatment). 
 
Figure 5 Exposure distribution of oxcarbazepine (OXC), R-(-)-MHD and S-(+)-MHD in healthy 
subjects. The histograms represent the simulated AUC0-12 distribution, the continuous line 
represent the median of the observed AUC0-12. Occasion O (OXC alone treatment); Occasion 
O+V (OXC+verapamil treatment). 
